FarmaMondo is pleased to announce the launch of its brand new website! After months of hard work and dedication, we are delighted to officially announce the launch on February 12, 2019. The new site launch is available and the URL is www.farmamondo.com The updated site includes changes to...

FarmaMondo Nordics Aps, a fully owned subsidiary of FarmaMondo SA, has received a GMP license from the Danish Medicines Agency. With this license in place, FarmaMondo Nordics provides a complete direct to hospital solution for Nordic region healthcare providers seeking the import and supply of unlicensed medicines through its...

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, will exclusively distribute Spectrila® via a Managed Access Program for targeted Healthcare Providers in Russia and CIS region. FarmaMondo to manage access to Spectrila® for patients with acute lymphoblastic leukemia in Russia, Georgia, Azerbaijan, Kyrgyzstan, Uzbekistan, Moldova. Spectrila® has been...

Merck’s Keytruda (Pembrolizumab) showed better results than chemotherapy at improving overall survival among first-line patients with non-small cell lung cancer in a trial whose results were published last Monday. The benefit extended across PD-L1-positive patients in the study, regardless of their level of PD-L1 expression.  Keytruda is the first...

AstraZeneca’s Tagrisso has been approved by FDA as a first-line treatment for patients with metastatic non-small-cell lung cancer characterized by epidermal growth factor receptor (EGFR) mutations. Tagrisso is already approved in the US as a second-line treatment for this subgroup of lung cancer patients, whose disease...

FarmaMondo Team is pleased to inform you that  is attending Pharmagora Paris 2018. PharmagoraPlus has been the single largest conference and exhibition in France dedicated to serving the pharmacy market for over 30 years. The show brings together all major players under one roof including Ordre National des Pharmaciens, pharmacies‘ buying...

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by Amomed Pharma to exclusively distribute Empressin® via a Managed Access Program for targeted Healthcare Providers in Russia and CIS region. FarmaMondo to manage access to Empressin for patients with septic shock in Russia, Belarus, Kazakhstan,...

FarmaMondo celebrates the recent successful establishment of its subsidiary in Copenhagen covering all 5 Nordic countries representing more than 27 million people. The Nordic expansion comes as a follow up to previous successful expansion to LATAM, Asia and CIS regions. FarmaMondo continues to invest...

Read the full interview, appeared on the magazine Healthcare and Life Sciences Review with our CEO, Mr. Jaron Spigel, regarding the uniqueness of FarmaMondo business model. With two billion people globally – predominantly in low and middle-income countries – having little or no access to medicine, a select group...